Trial
NCT07060365
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
Parexel
Condition
Advanced/Recurrent Ovarian Cancer
Intervention
Saruparib
Why stopped
The study termination is based on Sponsor decision and is not related to any safety, efficacy or quality concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-03